X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ALEMBIC LTD - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE ALEMBIC LTD STRIDES PHARMA SCIENCE/
ALEMBIC LTD
 
P/E (TTM) x 51.1 50.2 101.8% View Chart
P/BV x 1.1 2.1 51.8% View Chart
Dividend Yield % 0.4 0.5 92.0%  

Financials

 STRIDES PHARMA SCIENCE   ALEMBIC LTD
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ALEMBIC LTD
Mar-18
STRIDES PHARMA SCIENCE/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,14772 1,593.1%   
Low Rs64234 1,893.8%   
Sales per share (Unadj.) Rs317.24.7 6,749.1%  
Earnings per share (Unadj.) Rs7.86.1 128.5%  
Cash flow per share (Unadj.) Rs25.16.2 401.2%  
Dividends per share (Unadj.) Rs2.000.20 1,000.0%  
Dividend yield (eoy) %0.20.4 59.2%  
Book value per share (Unadj.) Rs274.340.7 674.5%  
Shares outstanding (eoy) m89.50267.03 33.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.811.3 25.0%   
Avg P/E ratio x114.08.7 1,314.4%  
P/CF ratio (eoy) x35.78.5 421.1%  
Price / Book Value ratio x3.31.3 250.5%  
Dividend payout %25.53.3 778.1%   
Avg Mkt Cap Rs m80,05814,139 566.2%   
No. of employees `0002.5NA-   
Total wages/salary Rs m4,341207 2,092.8%   
Avg. sales/employee Rs Th11,325.8NM-  
Avg. wages/employee Rs Th1,731.4NM-  
Avg. net profit/employee Rs Th280.1NM-  
INCOME DATA
Net Sales Rs m28,3941,255 2,262.1%  
Other income Rs m941370 254.1%   
Total revenues Rs m29,3341,625 1,804.7%   
Gross profit Rs m3,965111 3,569.2%  
Depreciation Rs m1,54038 4,075.1%   
Interest Rs m1,9622 115,435.3%   
Profit before tax Rs m1,403442 317.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1681,212 -13.9%   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m9724 406.3%   
Profit after tax Rs m7021,630 43.1%  
Gross profit margin %14.08.9 157.8%  
Effective tax rate %6.95.4 127.9%   
Net profit margin %2.5129.8 1.9%  
BALANCE SHEET DATA
Current assets Rs m24,8361,867 1,330.2%   
Current liabilities Rs m18,993591 3,212.6%   
Net working cap to sales %20.6101.6 20.2%  
Current ratio x1.33.2 41.4%  
Inventory Days Days7194 75.3%  
Debtors Days Days11374 154.2%  
Net fixed assets Rs m34,2891,791 1,914.6%   
Share capital Rs m895534 167.6%   
"Free" reserves Rs m23,65110,324 229.1%   
Net worth Rs m24,54610,858 226.1%   
Long term debt Rs m15,51341 37,653.4%   
Total assets Rs m65,43711,591 564.6%  
Interest coverage x1.7260.9 0.7%   
Debt to equity ratio x0.60 16,655.9%  
Sales to assets ratio x0.40.1 400.7%   
Return on assets %4.114.1 28.9%  
Return on equity %2.915.0 19.1%  
Return on capital %6.915.2 45.4%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m15,69719 80,912.9%   
Fx outflow Rs m735264 278.8%   
Net fx Rs m14,962-244 -6,121.3%   
CASH FLOW
From Operations Rs m1,871236 793.3%  
From Investments Rs m5,826-224 -2,600.8%  
From Financial Activity Rs m-10,157-27 38,183.8%  
Net Cashflow Rs m-2,615-15 17,668.2%  

Share Holding

Indian Promoters % 27.7 64.0 43.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 0.2 18,900.0%  
FIIs % 8.6 9.7 88.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 26.1 99.2%  
Shareholders   56,241 54,701 102.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   WOCKHARDT LTD.  J.B.CHEMICALS  MERCK LTD  BIOCON LTD  FULFORD INDIA  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Brexit Deal; Key Q2FY19 Results & Top Stocks in Focus Today(Pre-Open)

On Thursday, Indian share markets ended marginally higher led by bank stocks and finance stocks. At the closing bell, the BSE Sensex ended up by 119 points.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

Which Equity Mutual Funds to Buy Now?(Outside View)

Nov 13, 2018

PersonalFN explains that in falling markets investing in equity mutual funds can be beneficial in long run by choosing the right equity mutual fund scheme.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 15, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - J.B.CHEMICALS COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS